Quantum Genomics strengthend its organization and management team with the appointment of Dr. Olivier Madonna as Chief Medical Officer of the company. Olivier Madonna will be in charge of the clinical developments of Quantum Genomics' drug candidates and of the relations with regulatory authorities and drug safety agencies. He will also lead the work on patients' stratification and products positioning.

livier Madonna has a broad international experience as head of medical departments of pharmaceutical and biotechnology companies. At Merck & Co, he acquired an in depth knowledge of the clinical development of antihypertensive drugs, such as Angiotensin-Converting Enzyme (ACE) inhibitors or Angiotensin II Receptor Blockers (ARBs).